{
    "Trade/Device Name(s)": [
        "IDS-iSYS Free Testosterone",
        "IDS Free Testosterone"
    ],
    "Submitter Information": "Immunodiagnostic Systems Limited",
    "510(k) Number": "K240865",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181017"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "September 20, 2024",
    "Summary Letter Received Date": "September 20, 2024",
    "Submission Date": "September 20, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone Test System"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Free testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Standard sampling tubes",
        "Serum separator tubes (SST)",
        "Lithium heparin tube",
        "Sodium heparin tube",
        "Potassium (K2) EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "IDS-iSYS Multi-Discipline Automated System"
    ],
    "Method(s)/Technology(ies)": [
        "Competitive immunoassay",
        "Chemiluminescence"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for IDS-iSYS Free Testosterone competitive chemiluminescent immunoassay for quantifying free testosterone in serum or plasma on the IDS-iSYS system.",
    "Indications for Use Summary": "Quantitative determination of free testosterone in human serum or plasma to aid in diagnosis and treatment of disorders involving male sex hormones, including hypogonadism, impotence, hirsutism, virilization, polycystic ovaries, and androgenital syndromes.",
    "fda_folder": "Clinical Chemistry"
}